David R. Shalinsky

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

Michael R. Mancuso, Rachel Davis, Scott M. Norberg et al. · Journal of Clinical Investigation · 2006 · 798 citations · Full text

Medicine, Oncology, Pharmacology +14

Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts

Tetsuichiro Inai, Michael R. Mancuso, Hiroya Hashizume et al. · American Journal Of Pathology · 2004 · 763 citations · Full text

Medicine, Cancer Biology, Oncology +17

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

Medicine, Oncology, Pharmacology +17

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

Medicine, Oncology, Pharmacology +14

Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials

David R. Shalinsky, John Brekken, Helen Y. Zou et al. · Annals of the New York Academy of Sciences · 1999 · 238 citations

Medicine, Pharmacokinetics, Pharmacology +10